Eurofins Lancaster Laboratories and Celsis International Ltd. have announced that they have entered into a collaboration through which Eurofins Lancaster Laboratories will provide contract rapid microbiology validation and screening services for the Celsis rapid detection technology platform.
The Celsis rapid detection system allows companies to ensure that their products meet microbial specification 60 - 80% faster than traditional methods.
The decrease of as many as 7 to 10 days in production cycle times results in reduced inventories and working capital requirements in addition to providing earlier notification of microbial excursions when they occur.
“The pharmaceutical industry has begun to embrace the cost savings that the Celsis method can bring to their operations,“ said Judy Madden, Vice President of Corporate Development for Celsis. “We’re working with some of the pharmaceutical industry’s leaders to implement the Celsis method for microbial limits and sterility testing but many don’t have the resources or expertise to complete the validation work required before implementation. Eurofins Lancaster Laboratories’ expertise in this area will ensure high-quality validations and streamline the implementation process for our customers.”
With 50 years of delivering outstanding testing services, Eurofins Lancaster Laboratories has a stellar reputation for excellence in service quality and data reliability, enjoys long-standing relationships with many Fortune 500 clients and is part of the largest network of harmonized bio/pharmaceutical GMP product testing laboratories worldwide.
“We are pleased to have expanded our rapid technologies service offerings with the Celsis system in response to this industry need,” said Mark Kaiser, Director of Pharmaceutical Microbiology. “We have the Celsis system fully operational in both our US and Irish facilities, and both sites have initiated validation projects under contract. In addition to these, we anticipate that some of our current client base will move their routine microbiology testing to the Celsis method accelerating product release.”
Judy Madden added, “We’re excited that this collaboration will further advance the development of our pharmaceutical initiative by addressing an unmet market need.”